SC
RVMD icon

Stempoint Capital’s Revolution Medicines RVMD Stock Holding History

Stempoint Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$128K Sell
30,000
-70,000
-70% -$10.2M 0.02% 79
2026
Q1 		$525K Buy
+100,000
New +$10.1M 0.1% 70

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Stempoint Capital's RVMD Position: Q2 2026 in Review

Stempoint Capital reduced its Revolution Medicines (RVMD) stake by 43% in Q2 2026, selling an estimated $17.8M and leaving 159,943 shares worth $30M. The position accounts for 5.16% of the portfolio, ranked #3.

Stempoint Capital first reported a position in RVMD in Q3 2024 and has held it in 7 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Stempoint Capital held 159,943 shares of Revolution Medicines worth $30M as of Q2 2026.
  • Stempoint Capital sold 121,689 Revolution Medicines shares in Q2 2026, an estimated $17.8M.
  • Revolution Medicines made up 5.16% of Stempoint Capital's portfolio in Q2 2026, its #3 holding.
  • Stempoint Capital first reported a position in Revolution Medicines in Q3 2024 and has held it in 7 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.